EDEN PRAIRIE, MINN. — December 22, 2025 — Leads & Copy — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the appointment of Jason Mills to its Board of Directors, effective as of December 18, 2025.
Mills currently serves as Executive Vice President of Strategy at NYSE-listed Penumbra, Inc., where he leads long-range planning, FP&A, Business Development, and Investor Relations. Penumbra focuses on developing technologies for medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia. Before Penumbra, Mills was a med-tech investment analyst for over two decades.
Mills was Managing Director and head of the medical technology equity research practice at Canaccord Genuity for over 13 years. He has earned awards for his equity research, including the #2 ranked Medical Devices analyst in The Wall Street Journal’s 2011 ‘Best on the Street’ Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts. He holds a BA in Economics from Yale University and Masters in Sports Administration from Ohio University.
NeuroOne CEO Dave Rosa said Mills brings experience and insights in med-tech. Chairman Paul Buckman added that Mills will help expand the company’s reach as it transforms the diagnosis and treatment of neurological disorders.
NeuroOne (NASDAQ: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.
IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us
Source: NeuroOne Medical Technologies Corporation
